Abstract
Head-to-head trials comparing siponimod with fingolimod or ofatumumab in patients with multiple sclerosis (MS) are lacking. Instead, the comparative efficacy of siponimod can be derived from indire...
Funding Information
  • Novartis
  • Novartis Pharma AG

This publication has 31 references indexed in Scilit: